What Is International Stem Cell Corporation (ISCO) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, International Stem Cell Corporation is potentially undervalued at its current price of $0.29. Based on our 13-model framework, International Stem Cell Corporation's intrinsic value is estimated at a median fair value of $0.65 — representing +123.5% implied upside — with 2 out of 2 active models confirming this thesis. Model dispersion is worth noting: RCMH-DCF targets $0.80 (+175.0%), versus Bayesian DCF at $0.50 (+71.9%). This +103.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About ISCO?
2 of 13 models are currently active for ISCO. All 2 active models suggest the stock trades below fair value. Taken together, their median fair value for ISCO is $0.65 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $0.50 on its own, implying +71.9% upside from the current price. See which stocks rank higher →
How Does ISCO Rank in Biotechnology?
Among 622 Biotechnology stocks, ISCO ranks #149 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 reflects mixed fundamentals.
See all Most Undervalued Biotechnology Stocks →
The Biotechnology sector introduces analytical considerations specific to biotechnology enterprise businesses. For International Stem Cell Corporation, metrics like R&D burn rate provide important context that general-purpose valuation models may underweight.
Is ISCO a Value Trap?
CirclFi's Value Trap algorithm assigns ISCO a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
2 of 13 models are active for International Stem Cell Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, International Stem Cell Corporation scores 6.0 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +103.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ISCO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ISCO's 2 active models, average confidence is 62%. Moderate confidence indicates reasonable fit.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad